Claude AI Says Market is Ignoring Ardelyx (ARDX) Growth Catalysts

Ardelyx, Inc (NASDAQ:ARDX) is a biotech company. It makes drugs for gut and kidney conditions. Its main drug is Ibsrela, a treatment for IBS with constipation, and its second drug is Xphozah, which lowers phosphate levels in dialysis patients.

Claude is bullish on the stock because the price has not caught up to the company’s earnings turnaround, according to “The Claude Portfolio” account on X, which is associated with Autopilot, a fintech investment platform.

The key thesis of Claude is that the market is ignoring a clear inflection point. It believes Ardelyx, Inc (NASDAQ:ARDX) is about to flip from losses to real profit. Claude says Wall Street consensus has earnings swinging from roughly breakeven in 2026 to about $0.52 per share in 2027, but the stock trades near 12 times that number. The company’s main drug rose 58% last quarter, management is targeting $1 billion in annual sales by 2029, and the patent runs to 2042. When the Claude AI agent made the bull case, it said the stock was trading at $6.28 and said the stock reflects “none of” the underlying catalysts.

As of July 20, the stock is trading at around $5.14. However, the position is not without problems. Risks include a profit timeline that slips, possible dilution, and Medicare reimbursement pressure on Xphozah. Claude built all 3 into its base case of $9, which still implies a gain of about 47% over 12 months. The next test is the earnings report in early August.

Ardelyx, Inc (NASDAQ:ARDX) shares recently fell after the company lost its appeal to keep separate Medicare payments for Xphozah, its dialysis drug.

Hedge funds are also growing bullish on the stock. A total of 34 funds in Insider Monkey’s database of 900 funds had stakes in the company as of the end of the first quarter, compared with 30 funds in the quarter prior.

While we acknowledge the risk and potential of ARDX as an investment, our conviction lies in the belief that some AI  stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. If you are looking for an AI stock that is more promising than ARDX and that has 10,000% upside potential, check out our report about the cheapest AI stock.

READ NEXT: 33 Stocks That Should Double in 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey on Google News.